<DOC>
	<DOCNO>NCT02485652</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety pharmacokinetics HM61713 patient T790M-positive non-small cell lung cancer ( NSCLC ) treatment epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKI ) .</brief_summary>
	<brief_title>Phase II Trial HM61713 Treatment ≥2nd Line T790M Mutation Positive Adenocarcinoma Lung</brief_title>
	<detailed_description>This single-arm , open-label , Phase 2 study assess anti-tumor efficacy oral single agent HM61713 administer patient T790M-positive NSCLC treatment EGFR-TKI measure objective response rate ( ORR ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Age : least 20 year age Cytologically histologically confirm adenocarcinoma locally advance metastatic NSCLC amenable curative surgery radiotherapy Radiologically confirm disease progression least one line treatment EGFRTKI At least one document EGFR mutation know related susceptibility EGFRTKIs ( include G719X , exon 19 deletion , L858R , L861Q ) World Health Organization ( WHO ) performance score 0 1 life expectancy least 3 month Centrally confirm T790M mutation positive tumor status tumor sample take confirmation disease progression recent anticancer treatment regimen At least one lesion ( exclude brain ) , previously irradiate accurately measure per RECIST version 1.1 Adequate hematological biological function Females childbearing potential must agree use adequate contraception 3 month last dose study drug Male patient document sterile agree use barrier contraception Recovery ≤ Grade 1 baseline toxicity , except stable sensory neuropathy ≤ Grade 2 alopecia Known history hypersensitivity active inactive excipients HM61713 drug similar chemical structure HM61713 Previous treatment anticancer therapy , EGFRTKI , HM61713 , drug target T790Mpositive mutant EGFR spar wildtype , investigational agent ( ) within 28 day prior first administration study drug , radiotherapy Any nonstudy related significant surgical procedure within past 28 day prior first administration study drug Spinal cord compression , leptomeningeal carcinomatosis active symptomatic brain metastasis History malignancy Clinically significant uncontrolled condition ( ) Active chronic pancreatitis Anyone cardiac abnormality history Presence history ILD , druginduced ILD , presence radiation pneumonitis Pregnant breast feeding In opinion investigator , patient unsuitable candidate receive HM61713</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>HM61713</keyword>
	<keyword>T790M-positive</keyword>
	<keyword>lung cancer</keyword>
	<keyword>Phase II</keyword>
	<keyword>Olmutinib</keyword>
</DOC>